Last updated: February 27, 2026
What Is the Drug Under NDC 67877-0444?
NDC 67877-0444 corresponds to Humira (adalimumab), a monoclonal antibody used for treating autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and others. The drug is marketed primarily by AbbVie.
Market Overview
Indications and Market Size
Humira is approved for multiple autoimmune diseases, contributing to its broad market penetration. The global autoimmune disease treatment market was valued at approximately USD 23 billion in 2022, with Humira capturing nearly 25% before biosimilar entry.
Competitive Landscape
Humira faces competition from biosimilars such as Amgen's Amjevita and Boehringer Ingelheim's Cyltezo, which entered various markets starting around 2016-2018. The biosimilar market growth impacts Humira's market share, especially in regions with early biosimilar adoption.
Patent Expiry and Biosimilar Entry
The original patent for Humira expired in the United States in January 2023. Multiple biosimilars launched that year, leading to significant pricing pressure, especially in the U.S.
Pricing Trends and Projections
Historical Pricing
-
Pre-biosimilar launch (2010-2022): U.S. list price for Humira was approximately USD 5,800 per month in 2022.
-
Post-biosimilar entry (2023 onward): Prices for biosimilars in the U.S. range between USD 3,000 and USD 4,500 per month, representing a reduction of 20-50%.
Price Expectations Over the Next Five Years
| Year |
Estimated Average Monthly Price (USD) |
Notes |
| 2023 |
USD 3,500 |
Biosimilar competition; price discounts increase. |
| 2024 |
USD 3,200 |
Market consolidation; further biosimilar launches. |
| 2025 |
USD 3,000 |
Price stabilization; biosimilar market mature. |
| 2026 |
USD 2,800 |
Continued downward pressure; possibly lower in some regions. |
| 2027 |
USD 2,700 |
Slight decline or stabilization depending on market access policies. |
Pricing Factors
- Region-specific pricing: U.S. prices are higher than Europe, where negotiated prices tend to be lower.
- Insurance coverage: Reimbursement policies influence actual transaction prices.
- Manufacturing costs: Biosimilar manufacturers leverage lower R&D costs, driving prices downward.
Revenue Projections
Estimates suggest that the current annual revenue for Humira in markets excluding biosimilar impact exceeds USD 20 billion. As biosimilars gain market share, revenue could decline by approximately 20-30% over the next three years in the U.S.
Impact of Biosimilars on Revenue
| Year |
Revenue Impact |
Comments |
| 2023 |
USD 15-17 billion |
Initial decline post-patent expiry. |
| 2024-2025 |
USD 12-14 billion |
Continued erosion with increased biosimilar adoption. |
Market Entry and Pricing Strategies
AbbVie plans to pivot post-Humira by developing and marketing next-generation drugs like Skyrizi (risankizumab) and Rinvoq (upadacitinib). These drugs target similar indications with potentially higher pricing and less generic pressure.
Key Takeaways
- Humira's patent expiry in the U.S. in January 2023 led to the entry of biosimilars, creating downward pressure on prices.
- The average monthly price is projected to decline from approximately USD 3,500 in 2023 to USD 2,700 by 2027.
- Revenue is expected to fall 20-30% over the next three years due to biosimilar competition.
- In markets outside the U.S., pricing pressure is less severe but still present, especially in Europe.
- The company's focus on innovative therapies aims to offset revenue decline from Humira biosimilars.
FAQs
1. Will Humira regain market share in the future?
Limited prospects due to biosimilar penetration; market share recovery unlikely unless new formulations or indications emerge with exclusivity.
2. How does biosimilar pricing affect overall medication costs?
Biosimilars typically price 20-50% lower than original biologics, reducing patient and payer costs.
3. What regions will see the most significant price reductions?
The U.S. will experience the steepest decline, followed by Europe; emerging markets may see less impact due to differing regulatory environments.
4. Are there potential regulatory challenges to biosimilar adoption?
Yes. Patent disputes and regulatory approvals can delay biosimilar market entry, influencing pricing stability.
5. How might new therapies influence Humira’s market?
Emerging treatments with improved efficacy or safety profiles can further cannibalize Humira’s market share, accelerating revenue decline.
References
- IQVIA. (2022). Global Biologic Market Data.
- FDA. (2023). Biosimilar approval announcements.
- EvaluatePharma. (2023). Worldwide biotech and pharmaceutical market forecasts.
- Statista. (2022). Humira pricing and sales data.
- ABPI. (2023). Biosimilar policy updates.
[1] FDA. (2023). Biologics License Applications (BLAs) approved. U.S. Food and Drug Administration.
